Ecothiopate is indicated to treat subacute or chronic angle-closure glaucoma post iridectomy, or when surgical treatment is contraindicated.
As a parasympathomimetic and organophosphate Ecothiopate binds irreversibly to cholinesterase. The slow rate that Echothiopate is hydrolyzed by cholinesterase may cause effects which can last one week or longer in the body.
Mode of Action:
The long-acting and irreversible ability of Ecothiopate to act as a topical cholinesterase inhibitor enhances the effects of endogenously liberated acetylcholine in parasympathetically innervated parts of the eye. Ecothiopate also increase the outflow of aqueous humor, thus causing a substantial decrease in intraocular pressure.
When administered as eye drops to patients diagnosed with glaucoma Ecothiopate forms an irreversible covalent bond with the ACh binding site on cholinesterase.
Toxic events have not been documented from Ecothiopate use, however, adverse effects may occur in a small number of patients. These adverse effects include cysts in the iris of the eye developing, stinging of the eye and burning of the eye.
2010-08, Curr Eye Res., 35(8):698-702.Toxicology and Applied Pharmacology. Volume 258, Issue 3, 1 February 2012.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs